Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis
Corporate updatesFor media and investors only
2025
Pharming Group reports on results of the 2025 Annual General Meeting of Shareholders
Corporate updatesPharming Group N.V. announces that at its Annual General Meeting of Shareholders (AGM) held today, all proposals were approved.
Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director
Corporate updatesPharming Group N.V. announces that the Company’s 2025 Annual General Meeting of Shareholders (the “AGM”) will be held on Wednesday June 11, 2025, at 14:00 CEST.
Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS
Corporate updatesFor media and investors only
Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders
Corporate updatesPharming Group N.V. announces today that the Extraordinary General Meeting of Shareholders (EGM) has adopted all proposals on the EGM agenda.
Pharming Group to convene Extraordinary General Meeting of Shareholders
Corporate updatesPharming Group N.V. announces it will hold an Extraordinary General Meeting of Shareholders (EGM) on March 4, 2025, at 14:00 CET.
Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer
Corporate updatesPharming Group N.V. announces today that the Board of Directors has nominated Fabrice Chouraqui to become Pharming’s new Executive Director and Chief Executive Officer, succeeding Sijmen de Vries.
2024
Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union
Corporate updatesPharming Group N.V. announces today an update on the ongoing review of its Marketing Authorisation Application (MAA) for leniolisib for the treatment of adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta syndrome (APDS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders
Corporate updatesPharming Group N.V. announces that at its Annual General Meeting of Shareholders (AGM) held today, all proposals were approved.
Pharming Group announces the 2024 Annual General Meeting of Shareholders
Corporate updatesPharming Group N.V. announces that the Company’s 2024 Annual General Meeting of Shareholders (the “AGM”) will be held on Tuesday, May 21, 2024 at 14:30 CEST.